



# THE UNIVERSITY *of* EDINBURGH

## Edinburgh Research Explorer

### Neuronal Activity and Its Role in Controlling Antioxidant Genes

**Citation for published version:**

Qiu, J, Dando, O, Febery, JA, Fowler, JH, Chandran, S & Hardingham, GE 2020, 'Neuronal Activity and Its Role in Controlling Antioxidant Genes', *International Journal of Molecular Sciences*, vol. 21, no. 6, pp. 1933. <https://doi.org/10.3390/ijms21061933>

**Digital Object Identifier (DOI):**

[10.3390/ijms21061933](https://doi.org/10.3390/ijms21061933)

**Link:**

[Link to publication record in Edinburgh Research Explorer](#)

**Document Version:**

Publisher's PDF, also known as Version of record

**Published In:**

International Journal of Molecular Sciences

**General rights**

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [openaccess@ed.ac.uk](mailto:openaccess@ed.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.





Review

# Neuronal Activity and Its Role in Controlling Antioxidant Genes

Jing Qiu <sup>1,2</sup>, Owen Dando <sup>1,2</sup> , James A. Febery <sup>2</sup>, Jill H. Fowler <sup>2</sup>, Siddharthan Chandran <sup>1,3</sup> and Giles E. Hardingham <sup>1,2,\*</sup>

<sup>1</sup> UK Dementia Research Institute, The Medical School, University of Edinburgh, Chancellor's Building, Edinburgh EH16 4SB, UK; Jing.Qiu@ed.ac.uk (J.Q.); Owen.Dando@ed.ac.uk (O.D.); Siddharthan.Chandran@ed.ac.uk (S.C.)

<sup>2</sup> Centre for Discovery Brain Sciences, University of Edinburgh, Hugh Robson Building, George Square, Edinburgh EH8 9XD, UK; james.febery@ed.ac.uk (J.A.F.); Jill.Fowler@ed.ac.uk (J.H.F.)

<sup>3</sup> Centre for Clinical Brain Sciences, University of Edinburgh Chancellor's Building, Edinburgh, EH16 4SB, UK

\* Correspondence: Giles.Hardingham@ed.ac.uk

Received: 29 January 2020; Accepted: 7 March 2020; Published: 12 March 2020



**Abstract:** Forebrain neurons have relatively weak intrinsic antioxidant defenses compared to astrocytes, in part due to hypo-expression of Nrf2, an oxidative stress-induced master regulator of antioxidant and detoxification genes. Nevertheless, neurons do possess the capacity to auto-regulate their antioxidant defenses in response to electrical activity. Activity-dependent  $Ca^{2+}$  signals control the expression of several antioxidant genes, boosting redox buffering capacity, thus meeting the elevated antioxidant requirements associated with metabolically expensive electrical activity. These genes include examples which are reported Nrf2 target genes and yet are induced in a Nrf2-independent manner. Here we discuss the implications for Nrf2 hypofunction in neurons and the mechanisms underlying the Nrf2-independent induction of antioxidant genes by electrical activity. A significant proportion of Nrf2 target genes, defined as those genes controlled by Nrf2 in astrocytes, are regulated by activity-dependent  $Ca^{2+}$  signals in human stem cell-derived neurons. We propose that neurons interpret  $Ca^{2+}$  signals in a similar way to other cell types sense redox imbalance, to broadly induce antioxidant and detoxification genes.

**Keywords:** neuroprotection; neurodegeneration; oxidative stress; signal transduction; synaptic activity; gene transcription; antioxidants; astrocytes

## 1. The Nrf2 Pathway Is Weak in Neurons

When placed alone in the absence of supporting glial cells, forebrain neurons have a lower capacity than astrocytes to withstand oxidative insults, particularly those involving peroxide exposure or generation. The principle peroxide-detoxifying system in non-neuronal cells, the glutathione (GSH) system, has low capacity in neurons compared to astrocytes and neurons store far less glutathione than their glial neighbors [1,2]. As a result they rely on nearby glia for antioxidant support: in response to oxidative stress astrocytes release glutathione which is broken down and taken up by neurons for their own use [3–7]. Other glutathione-utilizing enzymes (specifically glutathione transferase M2-2) have also been reported to be secreted by glia for uptake by neurons with neuroprotective consequences [8].

In astrocytes, as with many cell types, glutathione steady state levels are maintained through a feedback inhibitory mechanism whereby GSH inhibits the rate determining step in GSH biosynthesis, catalyzed by Glutamate-cysteine ligase (GCL). However, glutathione biosynthetic capacity is further regulated at the transcriptional level by a clever system that (most cells) possess to homeostatically regulate antioxidant, detoxification and cytoprotective genes in response to metabolic challenge. This

system is centered on the transcription factor Nrf2 [9–11], constitutively translated but ordinarily targeted for ubiquitin-mediated degradation by its inhibitor Keap1. However, in response to oxidative stress, one or more of Keap1's redox-sensitive cysteine residues become oxidized, preventing Nrf2's degradation, causing its accumulation and translocation to the nucleus [12,13]. Here, Nrf2 induces the expression of genes whose promoters contain its cognate binding site, referred to as the Antioxidant Response Element (ARE) [14]. Keap1 also possesses sensors for heavy metal stress, alkenals and nitric oxide, thus offering a variety of mechanisms by which cells sense stress and turn on a battery of ARE-containing genes [15,16]. In the brain, Nrf2 signaling is activated in astrocytes, contributing to ischemic preconditioning [16,17].

In contrast to astrocytes and most other cell types, forebrain neurons have a very weak Nrf2 pathway, due to expressing Nrf2 mRNA at very low levels, compared to astrocytes, in both rodent and human systems [3,18]. Moreover, what little Nrf2 is present in neurons is highly unstable [19]. As a result, any stresses that prevent Keap1-mediated degradation are ineffective simply because there is too little Nrf2 present in the first place [18]. Even genetic deletion of Keap1 has no effect on Nrf2 target genes in cortical neurons, unlike in other cell types such as astrocytes which exhibit a marked induction of basal expression of Nrf2 target genes. Examination of the relative level of expression of Nrf2 target genes reveals that they are much lower in neurons than astrocytes and that genetic deletion of Nrf2 lowers Nrf2 target gene expression in astrocytes, it has no effect in neurons [18]. Thus, Nrf2 contributes little to the basal expression of ARE-containing genes in neurons.

## 2. The Forebrain Neuronal Nrf2 Pathway Is Developmentally Shut off

The very low expression of Nrf2 in neurons compared to astrocytes is surprising given that both arise from the same population of neural progenitor cells. Interestingly, very young neurons do express quite high levels of Nrf2 and respond to Nrf2 activating stimuli with the accumulation of Nrf2 and induction of Nrf2 target genes [18]. However, as neurons mature, so levels of Nrf2 decline by a mechanism involving the epigenetic repression of the Nrf2 promoter leading to histone hypoacetylation around the Nrf2 transcription start site. The biological reason developing neurons should require the shut-off of the Nrf2 pathway is not fully understood, however clues have come from observing the effects of ectopically expressing Nrf2 in developing neurons at a time when it is ordinarily being repressed. While Nrf2 expression at this stage has the expected effect of enhancing antioxidant defenses and rendering neurons resistance to oxidative insults, it also had the effect of inhibiting development, with both dendritic outgrowth and arborization and synaptogenesis, severely retarded [18]. The basis of these effects by Nrf2 appears to be the repression of redox-sensitive signaling pathways critical for development, including the Wnt and c-Jun N-terminal kinase (JNK) pathways [18]. It remains to be seen whether Nrf2 pathway hypofunction is also a feature of other neuronal cell types, such as those in the cerebellum, striatum, midbrain and spinal cord, so the following sections apply primarily to cortical neurons.

## 3. Metabolic Adaption Induced by Neuronal Ca<sup>2+</sup> Signals

Neuronal Nrf2 levels remain low in maturity, robbing them of an important stress response pathway. It could be argued that neurons in particular would benefit from a functional Nrf2 pathway: they are highly metabolically active, consuming large amounts of adenosine triphosphate (ATP) to maintain their resting membrane potential. Moreover, their primary source of energy is oxidative phosphorylation, a process that can lead to reactive oxygen species (ROS) production when electrons escape the transport chain. Importantly, this energy requirement and attendant ROS production, increases dramatically when neurons are electrically active [20,21]. Rather than simply maintaining ionic balance and membrane potential in the face of leak currents, the neuron must restore these balances after membrane depolarization, clear the synapse of neurotransmitter and replenish vesicle pools, all of which involve energy-requiring transport against concentration gradients. To meet these increased demands for energy, neurons do not just rely on laws of mass action: Ca<sup>2+</sup> influx,

triggered following membrane depolarization (through voltage-gated  $\text{Ca}^{2+}$  channels) or excitatory neurotransmitter release (e.g., through glutamate-gated N-Methyl D-Aspartate (NMDA) receptors) actively promote oxidative phosphorylation. Cytoplasmic  $\text{Ca}^{2+}$  - activates the Aralar component of the malate–aspartate shuttle (MAS) which functions to deliver reducing equivalents into the mitochondria and promotes pyruvate production [22,23]. Additionally, mitochondrial  $\text{Ca}^{2+}$  triggers the activation (and dephosphorylation) of pyruvate dehydrogenase, as well as activating several  $\text{Ca}^{2+}$  dependent enzymes within the tricarboxylic acid (TCA) cycle [24–27]. Thus, activity-dependent  $\text{Ca}^{2+}$  signals help the neuron to meet elevated energy demands, however, the side effect is increased ROS production [26,28–32], GSH utilization [33] and consequent need for enhanced antioxidant capacity.

#### 4. Neuronal Regulation of Antioxidant Defenses


At face value, this coupling of enhanced ROS production to increased intrinsic antioxidant defenses would appear an ideal role for Nrf2 to play, however this mechanism is not available to neurons. Nevertheless, activity-dependent  $\text{Ca}^{2+}$  signals do lead to the transcriptional induction of antioxidant genes and consequently elevated capacity of both the glutathione and thioredoxin antioxidant systems [33–35]. For example, activity-dependent induction of catalytic (Gclc) and modifier (Gclm) subunits of glutamyl-cysteine ligase increase neuronal GSH biosynthesis capacity, boosting antioxidant defenses in vitro and in vivo. Indeed, reducing activity-dependent  $\text{Ca}^{2+}$  transients in vivo (by NMDAR antagonism) uncouples activity from Gclc expression, which leads to GSH depletion and neurodegeneration [33]. Interestingly, several of the antioxidant pathway genes induced by activity-dependent  $\text{Ca}^{2+}$  signals, such as Gclc, Gclm, Gsr, Srxn and Txnrd1 and Slc7a11 are known Nrf2 target genes, so how can neurons promote their expression if their Nrf2 pathway is not functional?

#### 5. Neuronal $\text{Ca}^{2+}$ Signals Can Induce Nrf2 Target Genes Independently of Nrf2

One fact often overlooked in the study of Nrf2 target genes is their potential to be controlled by transcription factors other than Nrf2. The transcription factor family AP-1 (Fos/Jun) is a known regulator of a number of known Nrf2 target genes, including Srxn1, Hmox1 and Nqo1. Interestingly, in these genes the Nrf2 binding ARE (typical consensus TMA<sub>n</sub>RTGA(Y/G)nnnGCR) contains an embedded AP-1 site. For example the mouse Srxn1 ARE sequence is TCACCCTGAGTCAGCG and the mouse Hmox1 ARE sequence is TCTGCTGAGTCAAGGTCCG (the AP-1 consensus sequences are underlined) [36,37]. Several studies have shown that AP-1 can contribute to the basal expression of ARE-containing genes, which can be further induced by Nrf2-activating stimuli [36]. Of course, most signal responsive promoters contain multiple elements, offering further scope for Nrf2-independent control of “Nrf2 target genes”. A well-studied example is the ARE-containing gene Slc7a11, which encodes the cystine/glutamate antiporter xCT. The Slc7a11 promoter also contains binding sites for the transcription factor ATF-4, offering an alternative route to its transcriptional regulation [38]. Given this, there is scope for Nrf2 target genes to be induced in a Nrf2-independent manner. This has been confirmed in the case of two examples: activity-dependent induction of mouse Srxn1 is Nrf2-independent [39] and AP-1 dependent [40], while activity-dependent induction of mouse Slc7a11 is Nrf2-independent and is ATF-4 dependent [41].

Thus, it is clear that certain Nrf2 target genes can be regulated by activity-dependent  $\text{Ca}^{2+}$  signals despite not having a functional Nrf2 pathway. However, it does not tell us what proportion of Nrf2 target genes can be controlled in this way by electrical activity. To gain an impression of this, we interrogated our previously reported RNA-seq data set of activity-dependent gene expression in human embryonic stem cell-derived neurons [42]. In this study we generated dissociated glutamatergic cortical-patterned neurons from human embryonic stem cells (hESC<sup>CORT</sup>-neurons) [43,44] and studied transcriptional responses to  $\text{Ca}^{2+}$  influx through L-type  $\text{Ca}^{2+}$  channel activation, achieved by KCl-induced membrane depolarization in the presence of the L-type  $\text{Ca}^{2+}$  channel agonist FPL64176 (KCl/FPL). Two timepoints were studied: 4 h and 24 h. We then cross-referenced this data set against a set of Nrf2-regulated genes, curated from an RNA-seq data set of astrocytes sorted from transgenic

mice which overexpress Nrf2 specifically in astrocytes [45] (GFAP-Nrf2). 59 genes are induced >2-fold in GFAP-Nrf2 astrocytes (relative to wild-type astrocytes) that were expressed > 1FPKM on average in the hESC<sup>CORT</sup>-neurons (data not shown). Of these 59 genes, 39 genes were found to be significantly induced in hESC<sup>CORT</sup>-neurons ( $p < 0.05$ ) at either 4 h or 24 h timepoints, including *GCLC*, *GCLM*, *GSR*, *NQO1*, *TXNRD1* *CAT* and *SLC7A11* and only 6 genes were significantly down-regulated (Figure 1).



**Figure 1.** Log<sub>2</sub> fold change of the indicated Nrf2-regulated genes in human embryonic stem cell (ESC)-derived cortical neurons stimulated with high K<sup>+</sup> for the indicated period of time. The data come from a meta-analysis of that published previously [42]. \*  $p < 0.05$  ( $n = 3$ ).

Collectively this illustrates that a substantial proportion of Nrf2-regulated genes can be controlled by Ca<sup>2+</sup> signals in human neurons. It makes teleological sense to mount an adaptive/protective response to Ca<sup>2+</sup> signals, since substantial or repetitive Ca<sup>2+</sup> influx into neurons places metabolic demands on neurons which may be unsustainable or injurious in the absence of adaption [46–49]. This type of metabolic homeostatic control regulated by Ca<sup>2+</sup> signals draws parallels with other Ca<sup>2+</sup>-dependent rebalancing processes in neurons, such as homeostatic plasticity of synaptic and intrinsic properties [50–52]. That said, Ca<sup>2+</sup> signals control several programs of cytoprotective gene expression that Nrf2 is not implicated in, such as the repression of apoptotic genes and FOXO-dependent gene expression [53,54], the induction of nuclear calcium and CREB-dependent pro-survival genes [55–58] and the manipulation of TrkB signaling [59]. Moreover, it is important to note that all the aforementioned effects of Ca<sup>2+</sup> signals are in response to non-toxic, physiological levels of Ca<sup>2+</sup>, excessive Ca<sup>2+</sup> influx, particularly through extrasynaptic NMDA receptors, induces a very different gene expression profile which has a net toxic, rather than protective effect [60–62].

## 6. Concluding Remarks

It remains to be seen whether Ca<sup>2+</sup> signals regulate Nrf2 target genes in other excitable cells, such as those of smooth and skeletal muscle or cell types where Ca<sup>2+</sup> signals herald major metabolic or developmental changes, such as oocytes and T-cells. Nevertheless, the overlap between the neuronal activity-dependent transcriptome and the Nrf2-regulated transcriptome suggest that neurons interpret Ca<sup>2+</sup> signals in a similar way to other cell types sense oxidative stress, to broadly induce antioxidant and cytoprotective genes to confer greater cellular resilience in the face of greater metabolic demand.



**Funding:** This work was funded by the UK Dementia Research Institute which receives its funding from DRI Ltd., funded by the UK Medical Research Council, Alzheimer's Society and Alzheimer's Research UK. J.H.F. was funded by a senior research fellowship from Alzheimer's Research UK (SRF2018B-005).

**Acknowledgments:** We thank Jeffrey Johnson for the GFAP-Nrf2 mouse.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

## References

1. Fernandez-Fernandez, S.; Almeida, A.; Bolanos, J.P. Antioxidant and bioenergetic coupling between neurons and astrocytes. *Biochem. J.* **2012**, *443*, 3–11. [[CrossRef](#)] [[PubMed](#)]
2. Dringen, R.; Pawlowski, P.G.; Hirrlinger, J. Peroxide detoxification by brain cells. *J. Neurosci. Res.* **2005**, *79*, 157–165. [[CrossRef](#)] [[PubMed](#)]
3. Shih, A.Y.; Johnson, D.A.; Wong, G.; Kraft, A.D.; Jiang, L.; Erb, H.; Johnson, J.A.; Murphy, T.H. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. *J. Neurosci.* **2003**, *23*, 3394–3406. [[CrossRef](#)] [[PubMed](#)]
4. Dringen, R.; Hirrlinger, J. Glutathione pathways in the brain. *Biol. Chem.* **2003**, *384*, 505–516. [[CrossRef](#)]
5. Vargas, M.R.; Johnson, J.A. The Nrf2-ARE cytoprotective pathway in astrocytes. *Expert Rev. Mol. Med.* **2009**, *11*, e17. [[CrossRef](#)]
6. Gupta, K.; Patani, R.; Baxter, P.; Serio, A.; Story, D.; Tsujita, T.; Hayes, J.D.; Pedersen, R.A.; Hardingham, G.E.; Chandran, S. Human embryonic stem cell derived astrocytes mediate non-cell-autonomous neuroprotection through endogenous and drug-induced mechanisms. *Cell Death Differ.* **2012**, *19*, 779–787. [[CrossRef](#)]
7. Diaz-Hernandez, J.I.; Almeida, A.; Delgado-Esteban, M.; Fernandez, E.; Bolanos, J.P. Knockdown of glutamate-cysteine ligase by small hairpin RNA reveals that both catalytic and modulatory subunits are essential for the survival of primary neurons. *J. Biol. Chem.* **2005**, *280*, 38992–39001. [[CrossRef](#)]
8. Cuevas, C.; Huenchuguala, S.; Munoz, P.; Villa, M.; Paris, I.; Mannervik, B.; Segura-Aguilar, J. Glutathione transferase-M2-2 secreted from glioblastoma cell protects SH-SY5Y cells from aminochrome neurotoxicity. *Neurotox. Res.* **2015**, *27*, 217–228. [[CrossRef](#)]
9. Dreger, H.; Westphal, K.; Weller, A.; Baumann, G.; Stangl, V.; Meiners, S.; Stangl, K. Nrf2-dependent upregulation of antioxidative enzymes: A novel pathway for proteasome inhibitor-mediated cardioprotection. *Cardiovasc. Res.* **2009**, *83*, 354–361. [[CrossRef](#)]
10. Hayes, J.D.; Dinkova-Kostova, A.T. The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. *Trends Biochem. Sci.* **2014**, *39*, 199–218. [[CrossRef](#)]
11. Zhu, H.; Jia, Z.; Zhang, L.; Yamamoto, M.; Misra, H.P.; Trush, M.A.; Li, Y. Antioxidants and phase 2 enzymes in macrophages: Regulation by Nrf2 signaling and protection against oxidative and electrophilic stress. *Exp. Biol. Med. (Maywood)* **2008**, *233*, 463–474. [[CrossRef](#)] [[PubMed](#)]
12. Higgins, L.G.; Kelleher, M.O.; Eggleston, I.M.; Itoh, K.; Yamamoto, M.; Hayes, J.D. Transcription factor Nrf2 mediates an adaptive response to sulforaphane that protects fibroblasts in vitro against the cytotoxic effects of electrophiles, peroxides and redox-cycling agents. *Toxicol. Appl. Pharmacol.* **2009**, *237*, 267–280. [[CrossRef](#)] [[PubMed](#)]
13. Ma, Q. Role of nrf2 in oxidative stress and toxicity. *Annu. Rev. Pharmacol. Toxicol.* **2013**, *53*, 401–426. [[CrossRef](#)] [[PubMed](#)]
14. Hayes, J.D.; McMahon, M.; Chowdhry, S.; Dinkova-Kostova, A.T. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. *Antioxid. Redox Signal.* **2010**, *13*, 1713–1748. [[CrossRef](#)]
15. McMahon, M.; Lamont, D.J.; Beattie, K.A.; Hayes, J.D. Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc and alkenals. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 18838–18843. [[CrossRef](#)]
16. Tebay, L.E.; Robertson, H.; Durant, S.T.; Vitale, S.R.; Penning, T.M.; Dinkova-Kostova, A.T.; Hayes, J.D. Mechanisms of activation of the transcription factor Nrf2 by redox stressors, nutrient cues and energy status and the pathways through which it attenuates degenerative disease. *Free Radic. Biol. Med.* **2015**, *88*, 108–146. [[CrossRef](#)]

17. Bell, K.F.; Al-Mubarak, B.; Fowler, J.H.; Baxter, P.S.; Gupta, K.; Tsujita, T.; Chowdhry, S.; Patani, R.; Chandran, S.; Horsburgh, K.; et al. Mild oxidative stress activates Nrf2 in astrocytes, which contributes to neuroprotective ischemic preconditioning. *Proc. Natl. Acad. Sci. USA* **2011**, *108*. [[CrossRef](#)]
18. Bell, K.F.; Fowler, J.H.; Al-Mubarak, B.; Horsburgh, K.; Hardingham, G.E. Activation of Nrf2-regulated glutathione pathway genes by ischemic preconditioning. *Oxid. Med. Cell Longev.* **2011**, *2011*, 689524. [[CrossRef](#)]
19. Bell, K.F.; Al-Mubarak, B.; Martel, M.A.; McKay, S.; Wheelan, N.; Hasel, P.; Markus, N.M.; Baxter, P.; Deighton, R.F.; Serio, A.; et al. Neuronal development is promoted by weakened intrinsic antioxidant defences due to epigenetic repression of Nrf2. *Nat. Commun.* **2015**, *6*, 7066. [[CrossRef](#)]
20. Jimenez-Blasco, D.; Santofimia-Castano, P.; Gonzalez, A.; Almeida, A.; Bolanos, J.P. Astrocyte NMDA receptors' activity sustains neuronal survival through a Cdk5-Nrf2 pathway. *Cell Death Differ.* **2015**, *22*, 1877–1889. [[CrossRef](#)]
21. Hall, C.N.; Klein-Flugge, M.C.; Howarth, C.; Attwell, D. Oxidative phosphorylation, not glycolysis, powers presynaptic and postsynaptic mechanisms underlying brain information processing. *J. Neurosci.* **2012**, *32*, 8940–8951. [[CrossRef](#)] [[PubMed](#)]
22. Harris, J.J.; Jolivet, R.; Attwell, D. Synaptic energy use and supply. *Neuron* **2012**, *75*, 762–777. [[CrossRef](#)]
23. Llorente-Folch, I.; Rueda, C.B.; Amigo, I.; del Arco, A.; Saheki, T.; Pardo, B.; Satrustegui, J. Calcium-regulation of mitochondrial respiration maintains ATP homeostasis and requires ARALAR/AGC1-malate aspartate shuttle in intact cortical neurons. *J. Neurosci.* **2013**, *33*, 13957–13971. [[CrossRef](#)] [[PubMed](#)]
24. Gellerich, F.N.; Gizatullina, Z.; Gainutdinov, T.; Muth, K.; Seppet, E.; Orynbayeva, Z.; Vielhaber, S. The control of brain mitochondrial energization by cytosolic calcium: The mitochondrial gas pedal. *IUBMB Life* **2013**, *65*, 180–190. [[CrossRef](#)] [[PubMed](#)]
25. Duchen, M.R. Ca(2+)-dependent changes in the mitochondrial energetics in single dissociated mouse sensory neurons. *Biochem. J.* **1992**, *283*, 41–50. [[CrossRef](#)]
26. Glancy, B.; Balaban, R.S. Role of mitochondrial Ca<sup>2+</sup> in the regulation of cellular energetics. *Biochemistry* **2012**, *51*, 2959–2973. [[CrossRef](#)]
27. Hasel, P.; McKay, S.; Qiu, J.; Hardingham, G.E. Selective dendritic susceptibility to bioenergetic, excitotoxic and redox perturbations in cortical neurons. *Biochim. Biophys. Acta* **2015**, *1853*, 2066–2076. [[CrossRef](#)]
28. Bas-Orth, C.; Schneider, J.; Lewen, A.; McQueen, J.; Hasenpusch-Theil, K.; Theil, T.; Hardingham, G.E.; Bading, H.; Kann, O. The mitochondrial calcium uniporter is crucial for the generation of fast cortical network rhythms. *J. Cereb. Blood Flow. Metab.* **2019**. [[CrossRef](#)]
29. Poyton, R.O.; Ball, K.A.; Castello, P.R. Mitochondrial generation of free radicals and hypoxic signaling. *Trends Endocrinol. Metab.* **2009**, *20*, 332–340. [[CrossRef](#)]
30. Hongpaisan, J.; Winters, C.A.; Andrews, S.B. Calcium-dependent mitochondrial superoxide modulates nuclear CREB phosphorylation in hippocampal neurons. *Mol. Cell Neurosci.* **2003**, *24*, 1103–1115. [[CrossRef](#)]
31. Hongpaisan, J.; Winters, C.A.; Andrews, S.B. Strong calcium entry activates mitochondrial superoxide generation, upregulating kinase signaling in hippocampal neurons. *J. Neurosci.* **2004**, *24*, 10878–10887. [[CrossRef](#)] [[PubMed](#)]
32. Brennan, A.M.; Suh, S.W.; Won, S.J.; Narasimhan, P.; Kauppinen, T.M.; Lee, H.; Edling, Y.; Chan, P.H.; Swanson, R.A. NADPH oxidase is the primary source of superoxide induced by NMDA receptor activation. *Nat. Neurosci.* **2009**, *12*, 857–863. [[CrossRef](#)] [[PubMed](#)]
33. Dryanovski, D.I.; Guzman, J.N.; Xie, Z.; Galteri, D.J.; Volpicelli-Daley, L.A.; Lee, V.M.; Miller, R.J.; Schumacker, P.T.; Surmeier, D.J. Calcium entry and alpha-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons. *J. Neurosci.* **2013**, *33*, 10154–10164. [[CrossRef](#)] [[PubMed](#)]
34. Baxter, P.S.; Bell, K.F.; Hasel, P.; Kaindl, A.M.; Fricker, M.; Thomson, D.; Cregan, S.P.; Gillingwater, T.H.; Hardingham, G.E. Synaptic NMDA receptor activity is coupled to the transcriptional control of the glutathione system. *Nat. Commun.* **2015**, *6*, 6761. [[CrossRef](#)] [[PubMed](#)]
35. Baxter, P.S.; Hardingham, G.E. Adaptive regulation of the brain's antioxidant defences by neurons and astrocytes. *Free Radic. Biol. Med.* **2016**, *100*, 147–152. [[CrossRef](#)] [[PubMed](#)]
36. Hardingham, G.E.; Lipton, S.A. Regulation of neuronal oxidative and nitrosative stress by endogenous protective pathways and disease processes. *Antioxid. Redox Signal.* **2011**, *14*, 1421–1424. [[CrossRef](#)]
37. Nguyen, T.; Yang, C.S.; Pickett, C.B. The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. *Free Radic. Biol. Med.* **2004**, *37*, 433–441. [[CrossRef](#)]

38. Soriano, F.X.; Baxter, P.; Murray, L.M.; Sporn, M.B.; Gillingwater, T.H.; Hardingham, G.E. Transcriptional regulation of the AP-1 and Nrf2 target gene sulfiredoxin. *Mol. Cells* **2009**, *27*, 279–282. [[CrossRef](#)]
39. Lewerenz, J.; Maher, P. Control of redox state and redox signaling by neural antioxidant systems. *Antioxid. Redox Signal.* **2011**, *14*, 1449–1465. [[CrossRef](#)]
40. Deighton, R.F.; Markus, N.M.; Al-Mubarak, B.; Bell, K.F.; Papadia, S.; Meakin, P.J.; Chowdhry, S.; Hayes, J.D.; Hardingham, G.E. Nrf2 target genes can be controlled by neuronal activity in the absence of Nrf2 and astrocytes. *Proc. Natl. Acad. Sci. USA* **2014**, *111*, E1818–E1820. [[CrossRef](#)]
41. Papadia, S.; Soriano, F.X.; Leveille, F.; Martel, M.A.; Dakin, K.A.; Hansen, H.H.; Kaindl, A.; Sifringer, M.; Fowler, J.; Stefovská, V.; et al. Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. *Nat. Neurosci.* **2008**, *11*, 476–487. [[CrossRef](#)] [[PubMed](#)]
42. Lewerenz, J.; Baxter, P.; Kassubek, R.; Albrecht, P.; Van Liefveringe, J.; Westhoff, M.A.; Halatsch, M.E.; Karpel-Massler, G.; Meakin, P.J.; Hayes, J.D.; et al. Phosphoinositide 3-kinases upregulate system xc(-) via eukaryotic initiation factor 2alpha and activating transcription factor 4-A pathway active in glioblastomas and epilepsy. *Antioxid. Redox Signal.* **2014**, *20*, 2907–2922. [[CrossRef](#)] [[PubMed](#)]
43. Qiu, J.; McQueen, J.; Bilican, B.; Dando, O.; Magnani, D.; Punovuori, K.; Selvaraj, B.T.; Livesey, M.; Haghi, G.; Heron, S.; et al. Evidence for evolutionary divergence of activity-dependent gene expression in developing neurons. *eLife* **2016**, *5*. [[CrossRef](#)] [[PubMed](#)]
44. Bilican, B.; Livesey, M.R.; Haghi, G.; Qiu, J.; Burr, K.; Siller, R.; Hardingham, G.E.; Wyllie, D.J.; Chandran, S. Physiological normoxia and absence of EGF is required for the long-term propagation of anterior neural precursors from human pluripotent cells. *PLoS ONE* **2014**, *9*, e85932. [[CrossRef](#)] [[PubMed](#)]
45. Livesey, M.R.; Bilican, B.; Qiu, J.; Rzechorzek, N.M.; Haghi, G.; Burr, K.; Hardingham, G.E.; Chandran, S.; Wyllie, D.J. Maturation of AMPAR composition and the GABAAR reversal potential in hPSC-derived cortical neurons. *J. Neurosci.* **2014**, *34*, 4070–4075. [[CrossRef](#)]
46. Vargas, M.R.; Johnson, D.A.; Sirkis, D.W.; Messing, A.; Johnson, J.A. Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. *J. Neurosci.* **2008**, *28*, 13574–13581. [[CrossRef](#)]
47. Soriano, F.X.; Hardingham, G.E. Compartmentalized NMDA receptor signalling to survival and death. *J. Physiol.* **2007**, *584*, 381–387. [[CrossRef](#)]
48. Wahl, A.S.; Buchthal, B.; Rode, F.; Bomholt, S.F.; Freitag, H.E.; Hardingham, G.E.; Ronn, L.C.; Bading, H. Hypoxic/ischemic conditions induce expression of the putative pro-death gene *Clca1* via activation of extrasynaptic N-methyl-D-aspartate receptors. *Neuroscience* **2009**, *158*, 344–352. [[CrossRef](#)]
49. Gupta, K.; Hardingham, G.E.; Chandran, S. NMDA receptor-dependent glutamate excitotoxicity in human embryonic stem cell-derived neurons. *Neurosci. Lett.* **2013**, *543*, 95–100. [[CrossRef](#)]
50. Bell, K.F.; Hardingham, G.E. CNS peroxiredoxins and their regulation in health and disease. *Antioxid. Redox Signal.* **2011**, *14*, 1467–1477. [[CrossRef](#)]
51. Turrigiano, G. Homeostatic synaptic plasticity: Local and global mechanisms for stabilizing neuronal function. *Cold Spring Harb. Perspect. Biol.* **2012**, *4*, a005736. [[CrossRef](#)] [[PubMed](#)]
52. Hardingham, N.R.; Hardingham, G.E.; Fox, K.D.; Jack, J.J. Presynaptic efficacy directs normalization of synaptic strength in layer 2/3 rat neocortex after paired activity. *J. Neurophysiol.* **2007**, *97*, 2965–2975. [[CrossRef](#)] [[PubMed](#)]
53. Hardingham, N.R.; Read, J.C.; Trevelyan, A.J.; Nelson, J.C.; Jack, J.J.; Bannister, N.J. Quantal analysis reveals a functional correlation between presynaptic and postsynaptic efficacy in excitatory connections from rat neocortex. *J. Neurosci.* **2010**, *30*, 1441–1451. [[CrossRef](#)] [[PubMed](#)]
54. Bell, K.F.; Hardingham, G.E. The influence of synaptic activity on neuronal health. *Curr. Opin. Neurobiol.* **2011**, *21*, 299–305. [[CrossRef](#)] [[PubMed](#)]
55. Al-Mubarak, B.; Soriano, F.X.; Hardingham, G.E. Synaptic NMDAR activity suppresses FOXO1 expression via a cis-acting FOXO binding site: FOXO1 is a FOXO target gene. *Channels Austin. Tex.* **2009**, *3*, 233–238. [[CrossRef](#)]
56. McKenzie, G.J.; Stevenson, P.; Ward, G.; Papadia, S.; Bading, H.; Chawla, S.; Privalsky, M.; Hardingham, G.E. Nuclear Ca<sup>2+</sup> and CaM kinase IV specify hormonal- and Notch-responsiveness. *J. Neurochem.* **2005**, *93*, 171–185. [[CrossRef](#)]



57. Baxter, P.S.; Martel, M.A.; McMahon, A.; Kind, P.C.; Hardingham, G.E. Pituitary adenylate cyclase-activating peptide induces long-lasting neuroprotection through the induction of activity-dependent signaling via the cyclic AMP response element-binding protein-regulated transcription co-activator 1. *J. Neurochem.* **2011**, *118*, 365–378. [[CrossRef](#)]
58. Zhang, S.J.; Zou, M.; Lu, L.; Lau, D.; Ditzel, D.A.; Delucinge-Vivier, C.; Aso, Y.; Descombes, P.; Bading, H. Nuclear calcium signaling controls expression of a large gene pool: Identification of a gene program for acquired neuroprotection induced by synaptic activity. *PLoS Genet.* **2009**, *5*, e1000604. [[CrossRef](#)]
59. Soriano, F.X.; Leveille, F.; Papadia, S.; Bell, K.F.; Puddifoot, C.; Hardingham, G.E. Neuronal activity controls the antagonistic balance between PGC-1 $\alpha$  and SMRT in regulating antioxidant defences. *Antioxid. Redox Signal.* **2011**, *14*, 1425–1436. [[CrossRef](#)]
60. Gomes, J.R.; Costa, J.T.; Melo, C.V.; Felizzi, F.; Monteiro, P.; Pinto, M.J.; Inacio, A.R.; Wieloch, T.; Almeida, R.D.; Graos, M.; et al. Excitotoxicity downregulates TrkB.FL signaling and upregulates the neuroprotective truncated TrkB receptors in cultured hippocampal and striatal neurons. *J. Neurosci.* **2012**, *32*, 4610–4622. [[CrossRef](#)]
61. Puddifoot, C.; Martel, M.A.; Soriano, F.X.; Camacho, A.; Vidal-Puig, A.; Wyllie, D.J.; Hardingham, G.E. PGC-1 $\alpha$  negatively regulates extrasynaptic NMDAR activity and excitotoxicity. *J. Neurosci.* **2012**, *32*, 6995–7000. [[CrossRef](#)] [[PubMed](#)]
62. Zhang, S.J.; Steijaert, M.N.; Lau, D.; Schutz, G.; Delucinge-Vivier, C.; Descombes, P.; Bading, H. Decoding NMDA Receptor Signaling: Identification of Genomic Programs Specifying Neuronal Survival and Death. *Neuron* **2007**, *53*, 549–562. [[CrossRef](#)] [[PubMed](#)]



© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).